Cytokinetics Inc CYTK
We take great care to ensure that the data presented and summarized in this overview for CYTOKINETICS INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding CYTK
View all-
T. Rowe Price Investment Management, Inc. Baltimore, MD19.1MShares$1.27 Billion0.64% of portfolio
-
Black Rock Inc. New York, NY14.7MShares$975 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.9MShares$788 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA7.41MShares$492 Million0.07% of portfolio
-
State Street Corp Boston, MA5.62MShares$373 Million0.01% of portfolio
-
Deep Track Capital, LP Greenwich, CT4.3MShares$286 Million7.46% of portfolio
-
Bank Of America Corp Charlotte, NC3.06MShares$203 Million0.01% of portfolio
-
Geode Capital Management, LLC Boston, MA3.04MShares$202 Million0.01% of portfolio
-
Polar Capital Holdings PLC London, X02.78MShares$185 Million0.82% of portfolio
-
Rtw Investments, LP New York, NY2.72MShares$181 Million2.0% of portfolio
Latest Institutional Activity in CYTK
Top Purchases
Top Sells
About CYTK
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a skeletal muscle troponin activator, which is in Phase III clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy; and CK-3772271, a small molecule cardiac myosin inhibitor that is in Phase I clinical trial. Cytokinetics, Incorporated has a strategic alliance with Astellas Pharma Inc. The company was incorporated in 1997 and is headquartered in South San Francisco, California.
Insider Transactions at CYTK
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 15
2026
|
James M Daly Director |
BUY
Grant, award, or other acquisition
|
Direct |
197
+50.0%
|
$12,411
$63.44 P/Share
|
|
Jan 15
2026
|
Wendell Wierenga Director |
BUY
Grant, award, or other acquisition
|
Direct |
98
+0.3%
|
$6,174
$63.44 P/Share
|
|
Jan 15
2026
|
Nancy Wysenski Director |
BUY
Grant, award, or other acquisition
|
Direct |
98
+0.32%
|
$6,174
$63.44 P/Share
|
|
Jan 15
2026
|
Robert Arthur Harrington Director |
BUY
Grant, award, or other acquisition
|
Direct |
197
+1.04%
|
$12,411
$63.44 P/Share
|
|
Jan 15
2026
|
John T Henderson Director |
BUY
Grant, award, or other acquisition
|
Direct |
334
+0.44%
|
$21,042
$63.44 P/Share
|
|
Jan 15
2026
|
Edward M. Md Kaye Director |
BUY
Grant, award, or other acquisition
|
Direct |
197
+1.9%
|
$12,411
$63.44 P/Share
|
|
Jan 05
2026
|
Andrew Callos EVP, Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
15,000
-22.92%
|
$900,000
$60.28 P/Share
|
|
Jan 05
2026
|
Andrew Callos EVP, Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+18.65%
|
$345,000
$23.26 P/Share
|
|
Jan 02
2026
|
Andrew Callos EVP, Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
1,798
-1.75%
|
$111,476
$62.63 P/Share
|
|
Jan 02
2026
|
Andrew Callos EVP, Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
885
+1.7%
|
$32,745
$37.63 P/Share
|
|
Dec 29
2025
|
Andrew Callos EVP, Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
1,809
-3.4%
|
$112,158
$62.44 P/Share
|
|
Dec 22
2025
|
Andrew Callos EVP, Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
675
-1.25%
|
$41,850
$62.72 P/Share
|
|
Dec 22
2025
|
Andrew Callos EVP, Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,177
+2.91%
|
-
|
|
Dec 22
2025
|
Fady Ibraham Malik EVP Research & Development |
SELL
Payment of exercise price or tax liability
|
Direct |
1,016
-0.71%
|
$62,992
$62.72 P/Share
|
|
Dec 22
2025
|
Fady Ibraham Malik EVP Research & Development |
BUY
Grant, award, or other acquisition
|
Direct |
4,000
+1.39%
|
-
|
|
Dec 22
2025
|
Robert I Blum President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
33,361
-4.12%
|
$2,168,465
$65.45 P/Share
|
|
Dec 22
2025
|
Robert I Blum President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
11,530
+1.42%
|
-
|
|
Dec 22
2025
|
Sung Lee EVP, Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
805
-1.11%
|
$49,910
$62.72 P/Share
|
|
Dec 22
2025
|
Sung Lee EVP, Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
4,304
+2.94%
|
-
|
|
Dec 22
2025
|
Robert I Blum President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
71,233
+7.98%
|
$427,398
$6.67 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 395K shares |
|---|---|
| Exercise of conversion of derivative security | 313K shares |
| Open market or private sale | 502K shares |
|---|---|
| Payment of exercise price or tax liability | 51.7K shares |
| Bona fide gift | 2.2K shares |